Clinical trials study new interventions (drugs or procedures) to evaluate their safety and effectiveness in humans. Trials follow a careful set of steps, allowing for the systematic gathering of information to answer questions and confirm hypotheses that were formed earlier, in either laboratory experiments or preliminary trials.
Contact: Deborah Sanfelice, (416) 946-4501 ext 2867, PMleukemiatrials@uhn.ca.
Contact: Kylie Martin, (416) 946-4501 ext 4750, PMleukemiatrials@uhn.ca.
Contact: Charina Cameron, (416) 946-4501 ext 5905, PMleukemiatrials@uhn.ca.
Contact: Kylie Martin, (416) 946-4501 ext 4750, PMleukemiatrials@uhn.ca.
Contact: Charina Cameron, (416) 946-4501 ext 5905, PMleukemiatrials@uhn.ca.
Contact: Kylie Martin, (416) 946-4501 ext 4750, PMleukemiatrials@uhn.ca.
Contact: Christine Puskar, (416) 946-4501 ext 4028, PMleukemiatrials@uhn.ca.
Contact: Deborah Sanfelice, (416) 946-4501 ext 2867, PMleukemiatrials@uhn.ca.
Contact: Charina Cameron, (416) 946-4501 ext 5905, PMleukemiatrials@uhn.ca.
Contact: Sumaira Vastani, (416) 946-4501 ext 2498, PMleukemiatrials@uhn.ca.
Contact: Deborah Sanfelice, (416) 946-4501 ext 2867, PMleukemiatrials@uhn.ca.
Contact: Deborah Sanfelice, (416) 946-4501 ext 2867, PMleukemiatrials@uhn.ca.
Contact: Charina Cameron, (416) 946-4501 ext 5905, PMleukemiatrials@uhn.ca.
Contact: Deborah Sanfelice, (416) 946-4501 ext 2867, PMleukemiatrials@uhn.ca.
Contact: Deborah Sanfelice, (416) 946-4501 ext 2867, PMleukemiatrials@uhn.ca.
Contact: Catherine Jang, (416) 946-4501 ext 4808, PMleukemiatrials@uhn.ca.
Contact: Christine Puskar, (416) 946-4501 ext 4028, PMleukemiatrials@uhn.ca.
Contact: Christine Puskar, (416) 946-4501 ext 4028, PMleukemiatrials@uhn.ca.
Contact: Kylie Martin, (416) 946-4501 ext 4750, PMleukemiatrials@uhn.ca.
Contact: Deborah Sanfelice, (416) 946-4501 ext 2867, PMleukemiatrials@uhn.ca.
Contact: Deborah Sanfelice, (416) 946-4501 ext 2867, PMleukemiatrials@uhn.ca.
Contact: Christine Puskar, (416) 946-4501 ext 4028, PMleukemiatrials@uhn.ca.
Contact: Sumaira Vastani, (416) 946-4501 ext 2498, PMleukemiatrials@uhn.ca.
Contact: Charina Cameron, (416) 946-4501 ext 5905, PMleukemiatrials@uhn.ca.
Contact: Sumaira Vastani, (416) 946-4501 ext 2498, PMleukemiatrials@uhn.ca.
Contact: Charina Cameron, (416) 946-4501 ext 5905, PMleukemiatrials@uhn.ca.
Contact: Kylie Martin, (416) 946-4501 ext 4750, PMleukemiatrials@uhn.ca.
Contact: Catherine Jang, (416) 946-4501 ext 4808, PMleukemiatrials@uhn.ca.
Contact: Sumaira Vastani, (416) 946-4501 ext 2498, PMleukemiatrials@uhn.ca.
Contact: Charina Cameron, (416) 946-4501 ext 5905, PMleukemiatrials@uhn.ca.
Contact: Hussein Mamdani, BSc, hmamdani@providencehealth.bc.ca, 604-806-9656.
Contact: Hussein Mamdani, BSc, hmamdani@providencehealth.bc.ca, 604-806-9656.
Contact: Hussein Mamdani, BSc, hmamdani@providencehealth.bc.ca, 604-806-9656.
NOTE: St. Paul’s Hospital site is only participating in the phase 2 portion of this study.
Contact: Tathiana Ruiz, truiz1@providencehealth.bc.ca, 604-682-2344 ext. 64987.
Contact: Tathiana Ruiz, truiz1@providencehealth.bc.ca, 604-682-2344 ext. 64987.
Contact: Tathiana Ruiz, truiz1@providencehealth.bc.ca, 604-682-2344 ext. 64987.
Contact: Prof. Dr. Norbert Vey, VEYN@ipc.unicancer.fr, +33 (4) 91223754.
Contact: Dr. Marie-Anne Hospital, hospitalm@ipc.unicancer.fr, +33 (4) 91227742.
Contact: Dr. Marie-Anne Hospital, hospitalm@ipc.unicancer.fr, +33 (4) 91227742.
Contact: Prof. Dr. Norbert Vey, VEYN@ipc.unicancer.fr, +33 (4) 91223754.
Contact: Prof. Dr. Norbert Vey, VEYN@ipc.unicancer.fr, +33 (4) 91223754.
Contact: Prof. Dr. Norbert Vey, VEYN@ipc.unicancer.fr, +33 (4) 91223754.
Contact: Prof. Dr. Norbert Vey, VEYN@ipc.unicancer.fr, +33 (4) 91223754.
Now Enrolling clinicaltrials.gov here.
Current Status: Part 1 recruitment complete; Part 2 (Phase 3) is now open for recruitment. For additional details, refer to the Geron press release (08 Aug 2019) at
http://ir.geron.com/news-releases/news-release-details/geron-starts-phase-3-clinical-trial-lower-risk-myelodysplastic
Geron Corporation is conducting a Phase 2/3 clinical study referred to as “IMerge”, with the study drug Imetelstat, which is a first-in-class telomerase inhibitor. With its novel mechanism of action, Imetelstat may provide clinical benefit to MDS patients. In this study, Imetelstat is administered as a 2-hour intravenous infusion every 28 days.
IMerge is a study for people with MDS who need blood transfusions due to anemia (low red blood cell counts). People with low or intermediate-1 risk MDS that has relapsed or is refractory to Erythropoiesis-Stimulating Agents (ESAs) treatment are to be enrolled in the study. This study is being conducted at multiple hospitals and institutions around the world, in approximately 90 sites globally. For more information about this clinical study, please visit www.clinicaltrials.gov (NCT02598661).
If have been diagnosed with myelodysplastic syndrome (MDS) with anemia, the Matterhorn clinical trial is a research study investigating a potential treatment to help treat your anemia and potentially reduce your need for blood transfusions.
Learn more at ClinicalTrials.gov.
Description: Oral ASTX727 LD in Lower Risk MDS
Study Title: A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
For more information on this study and a full list of eligibility requirements please visit www.clinicaltrials.gov, Identifier: NCT03502668 or. ASTX727-03LD@astx.com
A Phase 1 open-label, non-randomized immunotherapy trial to assess the safety of an adoptive T cell therapy for patients with higher risk myelodysplastic syndrome (MDS)
PersImmune, Inc., a San Diego based company founded in 2010, is developing a personalized adoptive cell therapy for myelodysplastic syndrome (MDS) using its proprietary PACTN (Personalized Adoptive immunotherapy by Cytotoxic T lymphocytes targeted to patient-specific neoplastic cell Neoantigens) technology. PACTN consists of an infusion of T cells that specifically recognize and destroy the patient’s neoplastic cells while sparing normal tissue. The therapy is intended for patients with intermediate, high, or very high risk MDS who have an inadequate response to or who decline standard therapy.
PersImmune has initiated enrollment of MDS patients in an open-label, non-randomized phase I clinical trial that will assess the safety of PACTN infusion for eligible patients. This approach uses patient’s own T-cells (collected when the patient is diagnosed with MDS) to target mutations uniquely expressed by the malignant cells but not by normal ones (MDS-specific). The primary endpoints of this trial are to assess the safety, tolerability and maximum tolerated dose of the T cell therapeutic product. The observational secondary endpoints include assessment of disease response and measurement of survival of the infused T cells.
The study will enroll 9 to 15 participants and is still recruiting new patients.
Eligibility criteria:
Additional information for physicians and health care providers interested in referring a patient with MDS is available at www.clinicaltrials.gov (NCT03258359)
This study is currently being conducted at only at the University of California, San Diego, Medical Center, but additional sites in southern California are being recruited to participate.
Study Description: A Phase 1/1b study for patients with MDS or AML that have been treated with at least one prior therapy and have a wild-type TP53 gene. MDS patients must have high-risk disease and have failed or relapsed after treatment with azacitidine or decitabine. Patients are being treated with the investigational drug ALRN-6924, either alone (MDS and AML patients) or in combination with a low dose of cytarabine (only MDS patients and some AML patients who recently transformed from MDS). Doses and schedules available may vary over time.
Study Title: A Phase 1/1b Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 alone and in combination with cytarabine (Ara-C) in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome with Wild-Type TP53
Key Inclusion Criteria:
Key Exclusion Criteria:
For more information on this study and a full list of eligibility requirements please visit www.clinicaltrials.gov, identifier NCT 02909972.
This study is currently being conducted at : Institute for Translational Oncology Research , Greenville, SC; Moffitt Cancer Center, Tampa, FL; Montefiore Einstein Cancer Center Bronx, NY; Oregon Health and Science University, Portland, OR; Sarah Cannon Research Institution, Denver, CO; Sarah Cannon Research Institution, Nashville, TN.
ALRN-6924 is an investigational agent and is not approved by the FDA or other regulatory agencies worldwide as a treatment for any indication
MDSF Center of Excellence, Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, is conducting a study on high dose vitamin C and its effect on the TET2 mutation in patients with MDS. Vitamin C may “tell” faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. Certain genetic changes are known to reduce the ability of an enzyme called TET2 to encourage stem cells to become mature blood cells, which eventually die, in many patients with certain kinds of leukemia and MDS, say the authors. This new study found that vitamin C activated TET2 function in mice engineered to be deficient in the enzyme.
The team at Perlmutter Cancer Center hopes that high doses of vitamin C will eventually be incorporated into cancer therapies. Vitamin C in combination with cancer drugs may provide an alternative approach.
You may be eligible for this study if you meet the following criteria:
Conditions:
Other Inclusion Criteria:
You may not be eligible for this study if the following are true:
If you are interested, please contact the MDSF or the Center of Excellence directly (Dr. Raoul Tibes via email at Raoul.Tibes@nyulangone.org).
PersImmune, Inc., a San Diego based company founded in 2010, is developing a personalized adoptive cell therapy for myelodysplastic syndrome (MDS) using its proprietary PACTN (Personalized Adoptive immunotherapy by Cytotoxic T lymphocytes targeted to patient-specific neoplastic cell Neoantigens) technology. PACTN consists of an infusion of T cells that specifically recognize and destroy the patient’s neoplastic cells while sparing normal tissue. The therapy is intended for patients with intermediate, high, or very high risk MDS who have an inadequate response to or who decline standard therapy.
PersImmune has initiated enrollment of MDS patients in an open-label, non-randomized phase I clinical trial that will assess the safety of PACTN infusion for eligible patients. This approach uses patient’s own T-cells (collected when the patient is diagnosed with MDS) to target mutations uniquely expressed by the malignant cells but not by normal ones (MDS-specific). The primary endpoints of this trial are to assess the safety, tolerability and maximum tolerated dose of the T cell therapeutic product. The observational secondary endpoints include assessment of disease response and measurement of survival of the infused T cells.
The study will enroll 9 to 15 participants and is still recruiting new patients.
Eligibility criteria:
Additional information for physicians and health care providers interested in referring a patient with MDS is available at www.clinicaltrials.gov (NCT03258359)
This study is currently being conducted at only at the University of California, San Diego, Medical Center, but additional sites in southern California are being recruited to participate.
Myelodysplastic Syndromes (MDS) remain difficult to treat, in part because these blood disorders are rare and researchers don’t have enough samples from patients to study. The National Myelodysplastic Syndromes Natural History Study is a chance to help improve MDS treatment in the future. For the first time ever in the U.S., this study will collect information and samples from patients with MDS, and follow those patients for years to answer questions about what causes MDS, how it gets worse over time, and what treatments are most likely to work. This National Institutes of Health (NIH) sponsored study will create a public resource by collecting clinical information and blood, bone marrow, and tissue samples from up to 2,000 people with, or suspected to have, MDS.
You may be eligible for this study if you are at least 18 years old and either:
OR
If you participate in this study, you will receive your normal care and treatment from your doctor but will not receive additional treatment as part of this study. Instead, your normal care and treatment will be followed. This will also include following your quality of life during your time on the study.
For more information on the study, including how to find a participating hospital near you, please visit the study website at https://thenationalmdsstudy.net/ or https://clinicaltrials.gov/ (NCT02775383).
Pfizer is conducting a clinical study to determine the safety, efficacy, PK and PD of Glasdegib (PF-04449913) or placebo when combined with azacitidine in patients with previously untreated Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) with 20-30% blasts and multi-lineage dysplasia, or Chronic Myelomonocytic Leukemia (CMML).
This study is being conducted at multiple hospitals and institutions around the world and includes two components: (a) a Phase 1b open -label safety lead in component and (b) a Phase 2 randomized double-blind component. In the Phase 1b component, approximately 10 patients will be enrolled and will receive Glasdegib (PF-04449913) and azacitidine and in the Phase 2 component, 160 patients will be randomized to receive to receive either Glasdegib (PF-04449913) (Arm A) or placebo (Arm B) in combination with azacitidine.
If you are a physician or health care provider and would like to refer a patient for enrollment into this clinical trial OR if you are an MDS, AML, or CMML patient please see additional information and contact details at the following websites:
This is a phase 2 study of selinexor for MDS patients (with up to 30% blasts) and CMML who have received prior decitabine or 5-azacytidine. The primary endpoint is to determine the response rate of this novel drug in patients who have refractory or relapsed disease after receiving either decitabine or 5-azacytidine.
Secondary Objectives of the study are to determine if selinexor improves the survival of people with MDS and CMML after receiving 5-azacytidine and CMML. Additional secondary endpoints include an assessment of response duration and tolerability of selinexor, and to perform research studies on blood and bone marrow samples to better understand the mechanism of selinexor in MDS and CMML.
NCT02228525
